7 results
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.
to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.
1. Clinically relevant reduction of symptom severity by use of Citrus/Cydonia comp. subcutaneous injections2. To examine the safety of treatment3. To examine treatment effects on immunological parameters4. To develop and validate an immunological…
Several observational studies have shown that Citrus/Cydonia comp. might be an effective treatment option for patients suffering from seasonal allergic rhinitis. In these studies Citrus/Cydonia comp. was either administered subcutaneously or given…
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
A non-inferiority/superiority trial was designed for the treatment of uncomplicated cystitis in the Dutch community, in which we compare a 1-day and 3-day regimen of FT to a 5-day regimen of nitrofurantoin to investigate the effect on time to…
To determine the anti-tumor activity, as defined as doubling of progression free survival (PFS) of vinorelbine treatment in patients with BRAF-like colon cancer.